HZ166

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530331

CAS#: 612527-56-7

Description: HZ-166 is a Positive GABAA receptor modulator and a GABAA receptor subtype-selective benzodiazepine site ligand. HZ166 is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Diminished GABAergic and glycinergic inhibition in the spinal dorsal horn contributes significantly to chronic pain of different origins. Accordingly, pharmacological facilitation of GABAergic inhibition by spinal benzodiazepines (BDZs) has been shown to reverse pathological pain in animals as well as in human patients.


Chemical Structure

img
HZ166
CAS# 612527-56-7

Theoretical Analysis

MedKoo Cat#: 530331
Name: HZ166
CAS#: 612527-56-7
Chemical Formula: C21H16N4O2
Exact Mass: 356.13
Molecular Weight: 356.385
Elemental Analysis: C, 70.77; H, 4.53; N, 15.72; O, 8.98

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: HZ-166; HZ 166; HZ166.

IUPAC/Chemical Name: ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate

InChi Key: ZSEDMNMFODMQRD-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H16N4O2/c1-3-14-8-9-17-15(11-14)19(16-7-5-6-10-22-16)23-12-18-20(21(26)27-4-2)24-13-25(17)18/h1,5-11,13H,4,12H2,2H3

SMILES Code: O=C(C1=C2N(C=N1)C3=CC=C(C#C)C=C3C(C4=NC=CC=C4)=NC2)OCC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 356.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yuan NY, Poe MM, Witzigmann C, Cook JM, Stafford D, Arnold LA. Characterization of GABA(A) receptor ligands with automated patch-clamp using human neurons derived from pluripotent stem cells. J Pharmacol Toxicol Methods. 2016 Nov - Dec;82:109-114. doi: 10.1016/j.vascn.2016.08.006. PubMed PMID: 27544543; PubMed Central PMCID: PMC5116268.

2: Paul J, Yévenes GE, Benke D, Di Lio A, Ralvenius WT, Witschi R, Scheurer L, Cook JM, Rudolph U, Fritschy JM, Zeilhofer HU. Antihyperalgesia by α2-GABAA receptors occurs via a genuine spinal action and does not involve supraspinal sites. Neuropsychopharmacology. 2014 Jan;39(2):477-87. doi: 10.1038/npp.2013.221. PubMed PMID: 24045508; PubMed Central PMCID: PMC3870792.

3: Fischer BD, Teixeira LP, van Linn ML, Namjoshi OA, Cook JM, Rowlett JK. Role of gamma-aminobutyric acid type A (GABAA) receptor subtypes in acute benzodiazepine physical dependence-like effects: evidence from squirrel monkeys responding under a schedule of food presentation. Psychopharmacology (Berl). 2013 May;227(2):347-54. doi: 10.1007/s00213-013-2975-2. PubMed PMID: 23354533; PubMed Central PMCID: PMC3637862.

4: Chen Q, Yim PD, Yuan N, Johnson J, Cook JM, Smith S, Ionescu-Zanetti C, Wang ZJ, Arnold LA, Emala CW. Comparison of cell expression formats for the characterization of GABA(A) channels using a microfluidic patch clamp system. Assay Drug Dev Technol. 2012 Aug;10(4):325-35. doi: 10.1089/adt.2011.415. PubMed PMID: 22574655; PubMed Central PMCID: PMC3419985.

5: Fischer BD, Atack JR, Platt DM, Reynolds DS, Dawson GR, Rowlett JK. Contribution of GABA(A) receptors containing α3 subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys. Psychopharmacology (Berl). 2011 May;215(2):311-9. doi: 10.1007/s00213-010-2142-y. PubMed PMID: 21190016; PubMed Central PMCID: PMC3097109.

6: Di Lio A, Benke D, Besson M, Desmeules J, Daali Y, Wang ZJ, Edwankar R, Cook JM, Zeilhofer HU. HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology. 2011 Mar;60(4):626-32. doi: 10.1016/j.neuropharm.2010.11.026. PubMed PMID: 21145329; PubMed Central PMCID: PMC3566476.

7: Fischer BD, Licata SC, Edwankar RV, Wang ZJ, Huang S, He X, Yu J, Zhou H, Johnson EM Jr, Cook JM, Furtmüller R, Ramerstorfer J, Sieghart W, Roth BL, Majumder S, Rowlett JK. Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure. Neuropharmacology. 2010 Dec;59(7-8):612-8. doi: 10.1016/j.neuropharm.2010.08.011. PubMed PMID: 20727364; PubMed Central PMCID: PMC2963662.